Testing tazbentetol for ALS safety and effectiveness
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests whether a drug called tazbentetol can help people with ALS. It aims to see if it is safe and slows the disease's progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a confirmed ALS diagnosis and a TRICALS risk score.
- You are on a stable dose of your current ALS treatment.
- You are not currently smoking or using nicotine products.
- You have not had a serious infection in the past month or an active cancer in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies an experimental drug called LTX-002 for people with ALS. It aims to see if the drug is safe and can slow down the disease.
This trial tests whether repetitive TMS (transcranial magnetic stimulation) can help people with ALS. It uses a special type of TMS that is repeated and measured. You would lie comfortably for about an hour while receiving the treatment.
This trial tests a new drug called TP04HN106 for people with ALS. It aims to see if it is safe and if it might slow down the disease. You may qualify if your breathing is still fairly good and you have been on a stable dose of riluzole.
This trial tests a new drug called VTx-002 to see if it is safe and tolerable for people with ALS. You may be able to join if you have had symptoms for less than 18 months and have a caregiver who can help.
This Phase 2 study tests tideglusib to see if it helps slow or improve amyotrophic lateral sclerosis (ALS). You may be eligible if you have early-stage ALS with preserved breathing ability and certain stable treatments.
This study tests a supplement called acetyl-L-carnitine (ALCAR) to see if it can slow the progression of ALS. It is for people in the early stages of the disease who are already taking riluzole and have good lung and muscle function.
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.